Ministry of Food and Drug Safety begins investigation into hyperlipidemia treatment that Daewon Pharmaceutical is producing on consignment

Reporter Kim Jisun / approved : 2023-10-13 03:07:11
  • -
  • +
  • 인쇄

 

[Alpha Biz=(Chicago) Reporter Kim Jisun] The Ministry of Food and Drug Safety has launched an investigation into the cause of the report that other drugs are included in the hyperlipidemia treatment "Rosuvastatin" of Dongkuk Pharmaceutical, which is being commissioned by Daewon Pharmaceutical.

According to the Ministry of Food and Drug Safety on the 12th, a report was recently received that a digestive medicine product was found in the Rosuvastatin product box. There are two packages of Rosuvastatin, 15 pills each, one of which was for stomach medicine.

Rosuvastatin, a hyperlipidemia complex of Dongkuk Pharmaceutical, is a product commissioned by Daewon Pharmaceutical at Hyangnam Plant in Hwaseong, Gyeonggi-do.

Daewon Pharmaceutical Co. said it is conducting a full investigation into the manufacturing line that produced the product on the same day and Dongkuk Pharmaceutical Co. is recalling the product.

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

주요기사

Korean Broadcasters Launch Copyright Lawsuit Against Naver Over AI Training Data2025.09.18
Paris Croissant Issues Voluntary Recall of “Dried Persimmon Pound Cake” Due to Allergen Labeling Omissio2025.09.18
Hyundai Motor Group Restores Vehicle Control Apps After 10-Hour Outage2025.09.18
HMM Completes Share Buyback Worth KRW 2.14 Trillion2025.09.18
Gyeonggi Police Arrest Two Chinese Nationals Over KT Mobile Payment Hacking Scheme2025.09.18
뉴스댓글 >

HEADLINE

건강이 보이는 대표 K Medical 뉴스

PHOTO

많이 본 기사